CoChat
Sign Up
Cited by 67Chemotherapy-induced organ toxicity mitigationAcute Kidney Injury ResearchChildhood Cancer Survivors' Quality of Life

Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance

Open access
Skinner, Roderick·2018·Pediatric Nephrology
DOI 10.1007/s00467-017-3662-zPMC PMC5769827
Open this paper in CoChat — free accountOpen PDF

Abstract

Chronic glomerular and tubular nephrotoxicity is reported in 20-50% and 20-25%, respectively, of children and adolescents treated with ifosfamide and 60-80% and 10-30%, respectively, of those given cisplatin. Up to 20% of children display evidence of chronic glomerular damage after unilateral nephrectomy for a renal tumour. Overall, childhood cancer survivors have a ninefold higher risk of developing renal failure compared with their siblings. Such chronic nephrotoxicity may have multiple causes, including chemotherapy, radiotherapy exposure to kidneys, renal surgery, supportive care drugs and tumour-related factors. These cause a wide range of chronic glomerular and tubular toxicities, often with potentially severe clinical sequelae. Many risk factors for developing nephrotoxicity, mostly patient and treatment related, have been described, but we remain unable to predict all episodes of renal damage. This implies that other factors may be involved, such as genetic polymorphisms influencing drug metabolism. Although our knowledge of the long-term outcomes of chronic nephrotoxicity is increasing, there is still much to learn, including how we can optimally predict or achieve early detection of nephrotoxicity. Greater understanding of the pathogenesis of nephrotoxicity is needed before its occurrence can be prevented.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00467-017-3662-z

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The renal glomerulus might be affected by cisplatin treatment in 60-80% of children and adolescents, and renal tubular function is affected by ifosfamide treatment in 20-25%.

    “The renal glomerulus might be affected by cisplatin treatment in 60-80% of children and adolescents and renal tubular function is affected by ifosfamide treatment in 20-25% 171 .”

    From Osteosarcoma (2022) · cites this paper as [171]

  • Cisplatin-induced glomerular effects are rarely severe enough to require treatment, but ifosfamide-induced renal tubular effects can lead to clinically relevant electrolyte wasting in the form of Fanconi syndrome.

    “Cisplatin-induced glomerular effects are rarely severe enough to require treatment but ifosfamide-induced renal tubular effects can lead to clinically relevant electrolyte wasting in the form of Fanconi syndrome 171 .”

    From Osteosarcoma (2022) · cites this paper as [171]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Skinner, R.
Affiliations
Great North Children's Hospital (GB)
Corresponding author
Skinner, Roderick
ORCID
Skinner, Roderick
Venue
Pediatric Nephrology
Publisher
Springer Science and Business Media LLC
Published
2017-04-22
Volume
33
Issue
2
Pages
215-225
ISSN
  • 0931-041X (ISSN-L)
  • 1432-198X
DOI
10.1007/s00467-017-3662-z
PMC
PMC5769827
OpenAlex
W2607407223
Cited by
67
References
76
Citations by year
2026: 6 · 2025: 6 · 2024: 6 · 2023: 10 · 2022: 15 · 2021: 8 · 2020: 5 · 2019: 7 · 2018: 3 · 2017: 1
FWCI
0.70
Type
journal article
Language
en
Open access
Licence
Locations
  • Pediatric Nephrology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
Newcastle University
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Chemotherapy-induced organ toxicity mitigation
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
Keywords
childhood cancer survivors, nephrotoxicity, ifosfamide, cisplatin, renal failure, risk factors, long-term outcomes, chemotherapy
MeSH terms
Antineoplastic Agents, Child, Cisplatin, Humans, Ifosfamide, Kidney, Kidney Diseases, Neoplasms, Risk Factors, Time Factors, Carboplatin, Survivors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review